Letter to the Editor
Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF-alpha antagonist therapy
Karin M. Dunst-Huemer MD,
Corresponding Author
Karin M. Dunst-Huemer MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
e-mail:
[email protected]Search for more papers by this author Christine Scheurecker MD,
Christine Scheurecker MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
Search for more papers by this author Josef Auboeck MD,
Josef Auboeck MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
Search for more papers by this author
Karin M. Dunst-Huemer MD,
Corresponding Author
Karin M. Dunst-Huemer MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
e-mail:
[email protected]Search for more papers by this author Christine Scheurecker MD,
Christine Scheurecker MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
Search for more papers by this author Josef Auboeck MD,
Josef Auboeck MD
Department of Dermatology and Venerology, General Hospital Linz, Linz, Austria
Search for more papers by this author
First published: 29 June 2013
No abstract is available for this article.
References
- 1Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol 2012; 39: 481.
- 2Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106.
- 3Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes 2008; 6: 75.
- 4Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167: 417.
- 5Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388.
